{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a start-up exclusive license to Great Lakes Neuroscience, Inc., which is located in Illinois, to practice the inventions embodied in the following patents: U.S. Patent 8,597,660, issued December 3, 2013 (HHS reference E-144-2010/0-US-02). The patent rights in these inventions have been assigned to the United States of America. The prospective start-up exclusive license territory may be worldwide and the field of use may be limited to therapeutics for Multiple sclerosis, Acute Disseminated Encephalomyelitis (ADEM), Balo's disease, Clinically Isolated Syndrome, HTLV-1 Associated Myelopathy (HAM), Neuromyelitis optica and NMO spectrum disorder, Schilder's disease, Traverse myelitis, amyotrophic lateral sclerosis and other motor neuron diseases as follows: progressive bulbar palsy, primary lateral sclerosis, progressive muscular atrophy, spinal muscular atrophy, Kennedy's disease, and post polio syndrome.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/04/04/2016-07496.html","cfr_references":[],"citation":"81 FR 19213","comment_url":null,"comments_close_on":"2016-04-19","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by NINDS Technology Transfer on or before April 19, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-07496","effective_on":null,"end_page":19214,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/04/04/2016-07496.xml","html_url":"https://www.federalregister.gov/documents/2016/04/04/2016-07496/prospective-grant-of-start-up-exclusive-license-therapeutics-for-multiple-sclerosis-amyotrophic","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-07496?publication_date=2016-04-04","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-04-04/2016-07496/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":303,"last_updated":"2026-07-27 08:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-04-04/pdf/2016-07496.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-07496.pdf?1459514778","publication_date":"2016-04-04","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/04/04/2016-07496.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T21:18:41Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":19213,"subtype":null,"title":"Prospective Grant of Start-Up Exclusive License: Therapeutics for Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Certain Other CNS Disorders","toc_doc":"Therapeutics for Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Certain Other CNS Disorders","toc_subject":"Prospective Grant of Start-Up Exclusive License:","topics":[],"type":"Notice","volume":81}